Karen L. Reckamp, MD | Authors


An Analysis of a Phase II study MK-2206 plus Erlotinib in NSCLC

June 12, 2014

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.